Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health Inc (NY: HIMS )

16.06 -0.67 (-4.01%)
Streaming Delayed Price Updated: 3:03 PM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health Inc

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Hims & Hers Health Sees Major Growth Opportunity In Booming Weight Loss Market, Says Analyst
Needham analyst initiates coverage on Hims & Hers Health, Inc. with a Buy rating and $24 price target. Anticipates positive impact from GLP-1 market entry and strong growth potential. 
Via Benzinga
What Is Going On With Hims & Hers Stock?
After a strong start to the year, the stock is down 30% since June. 
Via The Motley Fool
The Latest Analyst Ratings For Hims & Hers Health
Via Benzinga
Looking Into Hims & Hers Health's Recent Short Interest
Via Benzinga
Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages
Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss drugs, despite legal battles and safety concerns surrounding its... 
Via Benzinga
2 Magnificent Stocks That Are Screaming Buys in August
These companies aren't slowing down. 
Via The Motley Fool
Hims & Hers Health Unusual Options Activity For August 13
Via Benzinga
Analyst Expectations For Hims & Hers Health's Future
Via Benzinga
How Is The Market Feeling About Hims & Hers Health?
Via Benzinga
Is Hims & Hers Health the Best Growth Stock for You?
Wall Street is missing the forest for the trees, and the opportunity is enormous. 
Via The Motley Fool
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
A small telemedicine company just entered the weight loss race. 
Via The Motley Fool
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
A company's investments can easily ruin the plans of its competitors. 
Via The Motley Fool
Top 3 Stocks to Watch: Options Traders Bet on Big Gains
Three stocks have stood out for call option traders to bet on in the coming months as a view for a recovery rally after an S&P 500 sell-off last week 
Via MarketBeat
Topics Stocks
Exposures US Equities
Hims & Hers Health Boosts Outlook. Is This a Golden Opportunity to Buy the Stock?
Growth is set to accelerate starting next quarter, powered by its GLP-1 offering. 
Via The Motley Fool
MarketBeat Week in Review – 8/5 - 8/9
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Hims & Hers Stock Crashed but This Is a Growth Machine
Don't overlook the 52% growth in the second quarter. 
Via The Motley Fool
Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
Hims & Hers stock is showing the market why its fair value is double-digits above where it trades today, with Wall Street analysts to agree 
Via MarketBeat
Topics Bonds ETFs
Exposures Debt Markets
HIMS Stock Earnings: Hims & Hers Health Beats EPS, Beats Revenue for Q2 2024
HIMS stock results show that Hims & Hers Health beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Hims & Hers Health Reports Better-Than-Expected Q2 Results: Details
Hims & Hers Health reported its second-quarter financial results Monday. Here's a look at the details from the report. 
Via Benzinga
Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results
From Hims & Hers
Via Business Wire
3 Telemedicine Stocks Poised for Possible Healthcare Evolution
Once the pandemic ended, so did the massive run in telemedicine stocks. However, there's still reason to buy. 
Via InvestorPlace
Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Hims & Hers stock is looking like a worthy dip to watch in the coming months, especially as its decline had nothing to do with company operations 
Via MarketBeat
Hims & Hers Stock Is Looking to Cash in From the GLP-1 Hype, but Will Its Controversial Strategy Pay Off?
Hims & Hers stock has been surging since May, but has its valuation gotten too rich? 
Via The Motley Fool
What's Going On With HIMS Shares Today?
Hims & Hers Health experienced a significant decline in its stock price on Thursday. Here's what you need to know. 
Via Benzinga
Got $200? 2 Best Growth Stocks to Buy and Hold Forever
Even a modest investment can help you start a position in quality stocks. 
Via The Motley Fool
Marker Rotation Is In Full Gear
We saw more new 52-week highs, and the number of 52-week lows was even lower than last week. The advance/decline in the NYSE looks better than the Nasdaq. 
Via Talk Markets
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
3 Game-Changing Stocks on the Edge of Unprecedented Gains
These three game-changing stocks appear ready to shift the valuation landscape and provide investors with outstanding returns. 
Via InvestorPlace
Can the New CEO Revive This Struggling Telehealth Stock?
Virtual healthcare provider Teladoc Health Inc. (NYSE: TDOC) stock is trading down 57.8% year-to-date (YTD). The collapse occurred after reporting Q4 2023 
Via MarketBeat
Topics Earnings
Exposures Financial
3 Once-in-a-Lifetime Stock Opportunities You Can’t Miss: July 2024
Discover three high-potential stocks in the tech, financial and healthcare sectors that can deliver significant returns. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.